Trials / Unknown
UnknownNCT05727397
Efficacy and Safety of RC28-E Versus Aflibercept
A Randomized, Double-Masked, Multicenter, Two-Arm Study Comparing the Efficacy and Safety of RC28-E 2mg Versus Aflibercept in Subjects With Wet Age-Related Macular Degeneration
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 432 (estimated)
- Sponsor
- RemeGen Co., Ltd. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double-masked, multicenter study comparing the the efficacy and safety of RC28-E injection (a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF-2) versus aflibercept in patients with wet age-related macular degeneration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RC28-E | Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 µL dose. |
| DRUG | Aflibercept | Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 µL dose. |
Timeline
- Start date
- 2023-03-14
- Primary completion
- 2025-11-29
- Completion
- 2025-12-29
- First posted
- 2023-02-14
- Last updated
- 2023-08-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05727397. Inclusion in this directory is not an endorsement.